A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Diabetes Mellitus, Type II

Treatments: Drug: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks; Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00482079

0431-010

2007_578

Details and patient eligibility

About

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Enrollment: 743 patients

Sex: All

Ages: 21 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 21 to 70, You are a man or non-pregnant woman

Exclusion criteria

• Have a history of type I diabetes
• You are on a weight loss program with ongoing weight loss or taking weight loss medications
• You have a history of minor surgery
• You have received investigational drugs within 8 weeks of study start
• You have hepatitis B or C

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind